Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Actuate Therapeutics, Inc. ( (ACTU) ) just unveiled an announcement.
On May 31, 2025, Actuate Therapeutics hosted a Key Opinion Leader event to discuss the Phase 2 data of elraglusib combined with gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. The event, featuring renowned experts, highlighted elraglusib’s potential impact on treatment paradigms by targeting various components of pancreatic tumors, including the tumor microenvironment and immune response, which could enhance its industry positioning.
The most recent analyst rating on (ACTU) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. operates in the biotechnology industry, focusing on developing treatments for cancer. Its primary product is elraglusib, which is being evaluated for its effectiveness in treating metastatic pancreatic cancer.
Average Trading Volume: 58,157
Technical Sentiment Signal: Strong Buy
Learn more about ACTU stock on TipRanks’ Stock Analysis page.